Insulin Glargine gives New Hope for those with Type-2 Diabetes in New Clinical Trials

Insulin Glargine CAS# 160337-95-1:

Insulin GlargineInsulin Glargine is basically used as a treatment for Type-1 diabetes, a condition in which the body is not able to produce enough insulin, and as a result, is unable to control the amount of sugar in the blood stream. It is also used for the treatment of Type-2 diabetes where the body is unable to use insulin normally. Insulin Glargine is a synthetic version of insulin which is long lasting and works by replacing the insulin which is naturally produced by the body in order to move sugar from the blood to other parts of the body, where it is stored and used for energy.

In recent clinical trials, a fixed ratio combination of Insulin Glargine along with Lixisenatide, which is a GLP-1 RA was shown to have superior reduction in the average blood glucose levels as compared to past clinical trials. Overall, the fixed ratio combination showed to have a safety profile which reflected those of insulin Glargine and Lixisentide. According to the researchers, the meeting of the primary objectives of this clinical trial showcases the clinical value of Insulin Glargine. The study is said to be completed by Q3 of 2015.

As suppliers/distributors to researchers for the development of anti-diabetic drugs, LGM Pharma is able to assist you in the supply of Insulin Glargine CAS# 160337-95-1 API. Rest assured you will get premium quality API products along with the continuous support of our team throughout the R&D process.

General Drug Facts:

Insulin Glargine is an analogue of human insulin which has been modified to provide a consistent supply of plasma insulin in those people who have been diagnosed with Type-1 and Type-2 diabetes. While the drug could also be used for other medical conditions it is not to be used by patients who are experiencing diabetic ketoacidosis.

General Disease Facts:

Both Type-1 and Type-2 diabetes can pose major problems for the body, which is one of the reasons why diabetes is called “the silent killer”. Out of the two, Type-2 diabetes is considered as the most common form of diabetes. Those who have Type-2 diabetes are unable to use insulin in the proper way, resulting in an increase of sugar in the blood. While the pancreas does make more insulin at the beginning to make up for the loss, over time, it is unable to keep up and cannot make enough insulin to keep blood glucose levels at a normal range. The condition is also known as insulin resistance.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.